Conditions: Macular Degeneration
Keywords: age-related macular degeneration (AMD) choroidal neovascularization (CNV) vascular endothelial growth factor (VEGF) pazopanib angiogenesis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 42
Healthy volunteers: no

Brief summary:
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.

Detailed description:

Arms:
arm 1: eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID) arm 2: eligible participants received 2 mg/ml Pazopanib eye drops three times daily arm 3: eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)

Interventions: intervention 1: Pazopanib
Intervention descriptions: intervention 1: 5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD

Protocol document: